Silo Pharma (SILO) completes $4,000,015 private exempt securities sale

Rhea-AI Filing Summary

Silo Pharma, Inc., a Nevada biotechnology corporation based in Sarasota, Florida, conducted an exempt private securities offering in reliance on Rule 506(b). The company reported a total amount sold of $4,000,015 and a total remaining to be sold of $0.

H.C. Wainwright & Co., LLC acted as placement agent and received $300,002 in cash commissions plus warrants to purchase up to 46,497 shares of common stock at an exercise price of $8.065 per share. The initial sale in this offering occurred on July 9, 2026.

Key Figures

Total amount sold: $4,000,015 USD Total remaining to be sold: $0 USD Placement agent commissions: $300,002 +3 more

6 metrics

Total amount sold $4,000,015 USD Aggregate amount of securities sold in the exempt offering

Total remaining to be sold $0 USD Reported remaining amount under the offering after sales

Placement agent commissions $300,002 Cash commissions paid to H.C. Wainwright & Co., LLC

Placement agent warrants 46,497 shares Warrants to purchase common stock issued as compensation

Warrant exercise price $8.065 per share Exercise price of warrants issued to H.C. Wainwright & Co., LLC

Date of first sale 2026-07-09 Initial sale date for securities in the exempt offering

Key Terms

Notice of Exempt Offering of Securities, Rule 506(b), covered securities, warrants to purchase

4 terms

Notice of Exempt Offering of Securities regulatory

"FORM D Notice of Exempt Offering of Securities"

Rule 506(b) regulatory

"Federal Exemption(s) and Exclusion(s) Claimed ... Rule 506(b)"

Rule 506(b) is a U.S. securities exemption that lets companies sell shares or debt privately without full public registration, provided sales are primarily to accredited investors, up to 35 non‑accredited but financially knowledgeable buyers, and there is no public advertising or solicitation. It matters to investors because offerings under 506(b) usually include less public disclosure than registered securities—like buying from a private seller rather than a retail store—so buyers must do more of their own fact‑checking and rely on their financial sophistication.

covered securities regulatory

"if the securities that are the subject of this Form D are "covered securities""

warrants to purchase financial

"warrants to purchase up to 46,497 shares of common stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/15/2026 - 11:18 AM Accepted by SEC EDGAR 07/14/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What type of financing did Silo Pharma (SILO) undertake in this filing?

Silo Pharma completed an exempt private securities offering in reliance on Rule 506(b), selling equity and related rights. The transaction was reported on Form D as a new notice of exempt offering, rather than a registered public securities offering.

How much capital did Silo Pharma (SILO) raise in this exempt offering?

Silo Pharma reported a total amount sold of $4,000,015 in the exempt offering. The filing also lists a total remaining to be sold of $0, indicating the full stated amount of the offering has been placed with investors.

Who acted as placement agent for Silo Pharma (SILO) and what compensation was paid?

H.C. Wainwright & Co., LLC served as placement agent for Silo Pharma. It received $300,002 in cash commissions and additional compensation in the form of warrants to purchase up to 46,497 shares of Silo Pharma’s common stock.

What warrants did H.C. Wainwright receive in the Silo Pharma (SILO) transaction?

In connection with the offering, H.C. Wainwright received warrants to purchase up to 46,497 shares of Silo Pharma common stock. These warrants are exercisable at an exercise price of $8.065 per share, providing potential future equity participation.

When did Silo Pharma (SILO) first sell securities in this Rule 506(b) offering?

The date of first sale in Silo Pharma’s exempt offering was July 9, 2026. This date marks when securities were initially sold to investors under the Rule 506(b) exemption described in the Form D notice.

Is this Silo Pharma (SILO) Form D notice a new filing or an amendment?

The Form D identifies the submission as a New Notice, not an amendment. It reports the initial exempt offering details, including total amount sold and the date of first sale, for the securities issued under Rule 506(b).

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001.

FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number:			3235-0076
Estimated average burden
hours per response:			4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous Names

None

Entity Type

0001514183

Uppercut Brands, Inc.

Point Capital, Inc.

Gold Swap Inc

X	Corporation
	Limited Partnership
	Limited Liability Company
	General Partnership
	Business Trust
	Other (Specify)

Name of Issuer

Silo Pharma, Inc.

Jurisdiction of Incorporation/Organization

NEVADA

Year of Incorporation/Organization

X	Over Five Years Ago
	Within Last Five Years (Specify Year)
	Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
Silo Pharma, Inc.
Street Address 1		Street Address 2
677 N. WASHINGTON BOULEVARD
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SARASOTA	FLORIDA	34236	(718) 400-9031

3. Related Persons

Last Name	First Name	Middle Name
Weisblum	Eric
Street Address 1	Street Address 2
677 N. WASHINGTON BOULEVARD
City	State/Province/Country	ZIP/PostalCode
SARASOTA	FLORIDA	34236

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Chief Executive Officer

Last Name	First Name	Middle Name
Ryweck	Daniel
Street Address 1	Street Address 2
677 N. WASHINGTON BOULEVARD
City	State/Province/Country	ZIP/PostalCode
SARASOTA	FLORIDA	34236

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Financial Officer

Last Name	First Name	Middle Name
Linsley	Wayne
Street Address 1	Street Address 2
677 N. WASHINGTON BOULEVARD
City	State/Province/Country	ZIP/PostalCode
SARASOTA	FLORIDA	34236

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Munoz	Kevin
Street Address 1	Street Address 2
677 N. WASHINGTON BOULEVARD
City	State/Province/Country	ZIP/PostalCode
SARASOTA	FLORIDA	34236

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Pavell	Jeff
Street Address 1	Street Address 2
677 N. WASHINGTON BOULEVARD
City	State/Province/Country	ZIP/PostalCode
SARASOTA	FLORIDA	34236

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture

Banking & Financial Services

Commercial Banking

Insurance

Investing

Investment Banking

Pooled Investment Fund

Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?

Yes No

Other Banking & Financial Services

Business Services

Energy

Coal Mining

Electric Utilities

Energy Conservation

Environmental Services

Oil & Gas

Other Energy

	Health Care
	Biotechnology
	Health Insurance
	Hospitals & Physicians
	X Pharmaceuticals
	Other Health Care
	Manufacturing
	Real Estate
	Commercial
	Construction
	REITS & Finance
	Residential
	Other Real Estate

Retailing

Restaurants

Technology

Computers

Telecommunications

Other Technology

Travel

Airlines & Airports

Lodging & Conventions

Tourism & Travel Services

Other Travel

Other

5. Issuer Size

Revenue Range		OR	Aggregate Net Asset Value Range
	No Revenues			No Aggregate Net Asset Value
	$1 - $1,000,000			$1 - $5,000,000
	$1,000,001 - $5,000,000			$5,000,001 - $25,000,000
	$5,000,001 - $25,000,000			$25,000,001 - $50,000,000
	$25,000,001 - $100,000,000			$50,000,001 - $100,000,000
	Over $100,000,000			Over $100,000,000
X	Decline to Disclose			Decline to Disclose
	Not Applicable			Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

		Rule 504(b)(1) (not (i), (ii) or (iii))
		Rule 504 (b)(1)(i)
		Rule 504 (b)(1)(ii)
		Rule 504 (b)(1)(iii)
	X	Rule 506(b)
		Rule 506(c)
		Securities Act Section 4(a)(5)

Investment Company Act Section 3(c)

Section 3(c)(1) Section 3(c)(9)

Section 3(c)(2) Section 3(c)(10)

Section 3(c)(3) Section 3(c)(11)

Section 3(c)(4) Section 3(c)(12)

Section 3(c)(5) Section 3(c)(13)

Section 3(c)(6) Section 3(c)(14)

Section 3(c)(7)

7. Type of Filing

X	New Notice			Date of First Sale	2026-07-09				First Sale Yet to Occur
	Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X	Equity		Pooled Investment Fund Interests
	Debt		Tenant-in-Common Securities
X	Option, Warrant or Other Right to Acquire Another Security		Mineral Property Securities
X	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient	Recipient CRD Number None
H.C. Wainwright & Co., LLC	000000375
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None
None	None
Street Address 1	Street Address 2
430 PARK AVENUE
City	State/Province/Country	ZIP/Postal Code
NEW YORK	NEW YORK	10022
State(s) of Solicitation (select all that apply) Check "All States" or check individual States All States	X Foreign/non-US
CALIFORNIA FLORIDA ILLINOIS NEW YORK

13. Offering and Sales Amounts

Total Offering Amount	$4,000,015	USD	or Indefinite
Total Amount Sold	$4,000,015	USD
Total Remaining to be Sold	$0	USD	or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

4

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	$300,002	USD	Estimate
Finders' Fees	$0	USD	Estimate

Clarification of Response (if Necessary):

In connection with the offering, H.C. Wainwright & Co., LLC received $300,002 in commissions and warrants to purchase up to 46,497 shares of common stock exercisable at $8.065 per share.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0

USD

Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

• Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

• Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Silo Pharma, Inc.	/s/ Eric Weisblum	Eric Weisblum	Chief Executive Officer	2026-07-14

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.